S&P Futures
4,275.75 -10.75 (-0.25%) Dow Futures
33,924.00 -57.00 (-0.17%) Nasdaq Futures
13,483.75 -39.50 (-0.29%) Russell 2000 Futures
1,993.50 -8.20 (-0.41%) Crude Oil
90.12 -0.38 (-0.42%) Gold
1,766.70 -4.50 (-0.25%)
Biocept, Inc. (BIOC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0800 |
| Open | 1.0700 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.0300 - 1.1000 |
| 52 Week Range | 0.8400 - 4.4000 |
| Volume | |
| Avg. Volume | 107,706 |
| Market Cap | 17.684M |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5240 |
| Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
SAN DIEGO, August 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended June 30, 2022, which ongoing review includes the analysis of previously reported material weaknesses and matters related to the U.S. Hea
- Fountain Asset Corp. Announces Its Financial Results for the Quarter Ended June 30, 2022GlobeNewswire
- Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability GuidanceGlobeNewswire
- Business Wire
Biocept Appoints RSM as Independent Auditor
SAN DIEGO, June 27, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today.
- GlobeNewswire
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’ ReSPECT-LM clinical trial AUSTIN, Texas and SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiot
